UPDATE: SPX-106T Arrests Development of Atherosclerotic Plaques in Mouse Model of Cardiovascular Disease

Spherix Incorporated (NASDAQ:

) – today announced that one of its drug candidates, SPX-106T, arrested development and reduced atherosclerotic plaque area in the aortic arch, thoracic aorta and sinus of Valsalva in mice genetically predisposed to cardiovascular disease. Atherosclerosis can lead to myocardial infarction (

) and stroke. Each year, about 770,000 people in the United States experience their first MI, and about one-third of these events are fatal.(1-3)